SCHEMBL7860893

SCHEMBL7860893

CC(=O)CNC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23015518 0.81
SCHEMBL19870668 0.80 ALOX15 (0.34)
SCHEMBL12119536 0.78
SCHEMBL7081593 0.78
SCHEMBL348669 0.78
Acetic Acid SCHEMBL27364283 0.77 FFAR3 (0.35)
Guanidino Acetate SCHEMBL28619528 0.77 EGLN1 (0.43)
Guanidino Acetate SCHEMBL1097127 0.77 CTH (0.40)
Guanidino Acetate SCHEMBL27413696 0.76 EGLN1 (0.41)
Guanidino Acetate SCHEMBL33970 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023286057-A1 NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES FORTEPHEST LTD (IL) 2023-01-19 WO disclosed
CN-111479875-B Moisture-curable composition 科思创德国股份有限公司 2022-11-15 CN disclosed
US-11352325-B2 Rapid fluorescence tagging of glycans and other biomolecules with enhanced MS signals WATERS TECHNOLOGIES CORPORATION (US) 2022-06-07 US disclosed
CN-113710746-A Two-component composition having high strength SIKA技术股份公司 2021-11-26 CN disclosed
EP-2897622-B1 METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION SYNEDGEN INC (US) 2021-04-21 EP disclosed
WO-2021034548-A1 MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-02-25 WO disclosed
CN-111479875-A Moisture-curable composition 科思创德国股份有限公司 2020-07-31 CN disclosed
CN-111479628-A Moisture-curable composition 科思创德国股份有限公司 2020-07-31 CN disclosed
EP-2555760-B1 CHITOSAN DERIVATIVES FOR THE TREATMENT OF MUCOSITIS OR ULCERATION SYNEDGEN INC (US) 2019-10-16 EP disclosed
US-20170304355-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. (US) 2017-10-26 US disclosed
WO-2010056896-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH SYNEDGEN, INC. (US) 2010-05-20 WO disclosed
WO-2009061597-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-05-14 WO disclosed
WO-2009061596-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-05-14 WO disclosed
WO-2009061595-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-05-14 WO disclosed
WO-2009052288-A1 SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2009-04-23 WO disclosed
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 US disclosed
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 US disclosed
US-20080194554-A1 Hiv Protease Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-08-14 US disclosed
US-20070281904-A1 Chitosan-derivative compounds and methods of controlling microbial populations UNITED STATES GOVERNMENT 2007-12-06 US disclosed
WO-2006104646-A1 HIV PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-05 WO disclosed